The Increasing Prevalence Of Autoimmune Diseases Is Fueling The Growth Of The Market Due To Rising Demand For TNF-Blocking Therapies: A Key Catalyst Accelerating Global Humira Biosimilar Market Growth in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Humira Biosimilar Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for Humira biosimilars has experienced swift expansion lately, projected to increase from its 2024 valuation of $3.28 billion to $3.67 billion by 2025, reflecting a compound annual growth rate (CAGR) of 12.0%. This substantial growth over the past period is attributable to several key factors, including the escalating need for budget-friendly substitutes, the growing number of biosimilars receiving official endorsement from regulatory agencies, the rising incidence of autoimmune conditions, broader healthcare availability within developing economies, and the substantial expense associated with the reference biologic drug.

Humira Biosimilar Market Size Forecast: What's the Projected Valuation by 2029?
Forecasting significant expansion, the market for Humira biosimilars is anticipated to boom over the coming years, achieving a valuation of $5.82 billion by the year 2029, driven by a compound annual growth rate (CAGR) of 12.3 percent; this upward trajectory through the projection timeframe stems from several factors, including progress in the technological aspects of biosimilar creation, escalating pressures to control healthcare expenditures, the expiration of exclusivity for numerous originator biologics, improvements in how biosimilars gain entry to markets and secure payment, alongside a growing tendency to utilize these alternatives, particularly in treating cancer and autoimmune conditions, while key developments shaping this era involve the regulatory clearance of additional biosimilar products, innovations in production methodologies, heightened investment in research and development efforts, the creation and subsequent authorization of biosimilar medications, and sophistication in how the drugs are prepared.

View the full report here:
https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

What Are the Drivers Transforming the Humira Biosimilar Market?
The rising incidence of conditions where the body's defense mechanisms mistakenly direct attacks against its own healthy components is projected to stimulate the expansion of the market for Humira biosimilars in the time ahead. These autoimmune maladies, often associated with environmental contaminants that interfere with immune function and raise susceptibility to self-attack, see their symptoms managed by Humira biosimilars, which function by inhibiting tumor necrosis factor (TNF), a pro-inflammatory agent central to these diseases, thereby mitigating excessive immune activity and safeguarding healthy tissues from harm; demonstrably, data from the Australian Institute of Health and Welfare indicated that in 2022, approximately 514,000 individuals in Australia, representing 2.0 percent of the population, were affected by rheumatoid arthritis, with the condition impacting 2.5 percent of women compared to 1.6 percent of men as of June 2024, underscoring how the heightened occurrence of self-reactive disorders is fueling momentum in the Humira biosimilar sector.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp

What Long-Term Trends Will Define the Future of the Humira Biosimilar Market?
Leading corporations within the Humira biosimilar sector are concentrating efforts on creating sophisticated treatments, specifically tumor necrosis factor (TNF) inhibitors, intending to present cost-effective alternatives for managing various autoimmune conditions. TNF inhibitors function as biological agents designed to subdue the effects of TNF, which is a crucial protein responsible for inciting inflammatory responses. Illustratively, during July 2023, the American pharmaceutical entity Organon & Co. entered into a collaboration with the South Korean biotechnology firm Samsung Bioepis Co., Ltd. for the introduction of HADLIMA, a biosimilar counterpart to Humira. HADLIMA has been made accessible in dual forms mirroring the original Humira offerings: a high-concentration formulation without citrate (100 mg/mL) and a lower-concentration version containing citrate (50 mg/mL), with the overarching goal of enhancing both patient accessibility and affordability. This medication is being introduced at a substantial price reduction, approximately 85 percent below Humira's established list rate, and incorporates patient assistance initiatives. This market entry was predicated upon a worldwide legal accord permitting its distribution within the United States, signifying a substantial advancement in widening therapeutic choices for persistent autoimmune ailments across the U.S.

Which Segments in the Humira Biosimilar Market Offer the Most Profit Potential?
The humira biosimilarmarket covered in this report is segmented -

1) By Product Type: Adalimumab Biosimilars; Other Types
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
3) By Application: Rheumatoid Arthritis; Psoriasis; Crohn's Disease; Ulcerative Colitis; Ankylosing Spondylitis; Other Applications

Subsegments:
1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies; Fragment Crystallizable (Fc) Region Modified Biosimilars; High-Concentration Formulations; Citrate-Free Formulations
2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors; Interchangeable Biosimilars; Pegylated Biosimilars; Non-Adalimumab Monoclonal Antibody Biosimilars

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24244&type=smp

Which Firms Dominate the Humira Biosimilar Market by Market Share and Revenue in 2025?
Major companies operating in the humira biosimilar market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Group AG, Fresenius Kabi AG, Celltrion Inc., Biocon Limited, Torrent Pharmaceuticals, Samsung Bioepis Co. Ltd., Alvotech, Coherus BioSciences Inc., Zydus Cadila, Hetero Drugs Ltd., Fujifilm Kyowa Kirin Biologics, Synermore Biologics, CVS Health.

Which Regions Offer the Highest Growth Potential in the Humira Biosimilar Market?
North America was the largest region in the humira biosimilar market in 2024. The regions covered in the humira biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24244

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.